anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a multicenter, randomized, double masked, placebo controlled Phase II trial to evaluate the safety and explore the efficacy of silymarin (Legalon®) compared with placebo on hepatic histology in patients with NASH (nonalcoholic steatohepatitis) after 48-50 weeks of therapy. This study was originally sponsored through a cooperative agreement (U01) award from the NCCAM and the NIDDK (RFA-AT-05-006: "Phase I/II Trials of Silymarin for Chronic Liver Diseases"), and now will continue with Madaus Inc. (Rottapharm Group) providing financial and regulatory support to the investigators. The broad aim of this study is to evaluate the safety and explore the efficacy of silymarin (Legalon®) in NASH patients and to form the basis for future studies which will establish its efficacy for treating patients with NASH. The specific objectives of this study are to determine the effect of silymarin (Legalon®) on the histologic NASH Activity Score (NAS), the liver enzymes, and HOMAr. The primary endpoint of the study is an improvement in the NAS by at least 2 points. Various secondary endpoints will be assessed, including the change in liver enzymes and HOMAr.
In this pharmaco-kinetic (PK) cross-over design trial, all patients initially receive nevirapine immediate release and then all patients are switched to nevirapine extended release 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).
BACKGROUND: Antibiotic use remains common for the treatment of lower respiratory tract infections. The objective of this study was to evaluate the impact of antibiotic use on the duration and severity of acute lower respiratory tract infection (LRTI).
PARTICIPANTS: Adult patients presenting to US primary or urgent care sites with a chief complaint of cough and symptoms consistent with LRTI.
MAIN MEASURES: Collected data included demographics, comorbidities, symptoms, and 48 viral and bacterial respiratory pathogens by PCR. Severity of signs/symptoms was reported for up to 28 days using diaries and text messages. Interpolation was used where data were missing.
KEY RESULTS: Of 718 patients with baseline data, 29% had an antibiotic prescribed at baseline. The most common antibiotics were amoxicillin-clavulanate, azithromycin, doxycycline, and amoxicillin in 85% of patients. Provision of an antibiotic had no effect on the duration or overall severity of cough, including in patients with viral, bacterial, and mixed infections. Receipt of an antibiotic did reduce the likelihood of a follow-up visit (14.1% vs 8.2%, aOR 0.47, 95% CI 0.26-0.84), perhaps by removing the motivation of getting an antibiotic at a follow-up visit. However, they were also more likely to receive a systemic corticosteroid (31.9% vs 4.5%, p < 0.001) and were also more likely to receive an albuterol inhaler (22.7% vs 7.6%, p < 0.001). Patients believed that receiving an antibiotic would reduce the duration of their illness by nearly 4 days.
CONCLUSIONS: In this large prospective study in the US primary and urgent care setting, antibiotics had no measurable impact on the severity or duration of cough due to acute LRTI. Patients had unrealistic expectations regarding the duration of LRTI and the effect of antibiotics which should be the target of antibiotic stewardship efforts.
PURPOSE: To provide a cleaner or conditioner for hair and skin by incorporating each specified amt. of an alkylpolyglycoside and an amphoteric polymer derived from a diallyldialkylammonium compound and acid monomers selected from acrylic acid and methacrylic acid. CONSTITUTION: This cleaning or conditioning compsn. for keratin substance (especially hair and skin) contains 0.1 to 40 wt.% alkylpolyglycoside expressed by formula I or formula II and 0.1 to 10 wt.% copolymer comprising 70 to 90 wt.% diallylalkylammonium units and 30 to 10 wt.% acid monomer selected from acrylic acid and methacrylic acid in a water medium, and the compsn. does not contain silicone as a conditioning agent or soap as a cleaning agent. In formula I, R is an 8 to 24C alkyl or alkenyl or mixture of them and (x) is 1 to 15. The obtd. compsn. is stable, and when it is used for hair, the hair is fast dried and easily combed.
Healthcare data is collected and managed. Biometric data of a healthcare consumer is received. A unique identifier is assigned to the healthcare consumer, and the unique identifier is associated with the biometric data. Healthcare data is received for the healthcare consumer. The health data is stored in association with the unique identifier. A request is received to access the health data. In accordance with determining that the request to access the health data is authorized, data is sent based on the health data in response to the request. In accordance with determining that the request to access the health data is not authorized, no data is sent based on the health data in response to the request.
BACKGROUND: With the aging of society, the prevalence of hearing loss (HL) is increasing. Currently, approximately 5% of the global population has HL, and this number is projected to reach 7 million by 2050. Although hearing aids (HAs) are the primary treatment for HL, their use is limited by barriers such as high costs and social stigma. To address these limitations, over-the-counter (OTC) HAs have been introduced, but their effectiveness and drawbacks require further investigation.
OBJECTIVE: This study aims to conduct a noninferiority randomized controlled trial comparing OTC HAs with traditional HAs to assess the clinical effectiveness of OTC HAs.
METHODS: We designed a noninferiority randomized controlled trial comparing OTC HAs and traditional HAs in adults with mild-to-moderate HL. A total of 64 participants (32 per group) will be recruited. Randomization will be performed using block randomization (block sizes of 2 or 4) with an equal allocation ratio. The study will include 2 types of HAs: an OTC HA (Jabra Enhance Pro) and a traditional HA (LiNX Quattro LE561-DRW) by GN ReSound A/S. OTC HAs will be self-fitted using a smartphone app, while traditional HAs will be fitted by a licensed audiologist using the National Acoustics Laboratories-Non-Linear Prescription, second generation. Assessments, including functional gain, real-ear measurement, speech audiometry, and questionnaires, will be conducted at 6-month intervals over the course of 3 visits. Statistical analysis will compare the 2 outcomes, focusing on functional gain, to determine noninferiority.
RESULTS: This study is scheduled to begin in August 2024 and has not yet recruited any participants. The study will be conducted over 2 years, from August 2024 to July 2026. Each participant will have 2 follow-up visits at 6-month intervals, making the total follow-up period 1 year.
CONCLUSIONS: Since 2022, the introduction of OTC HAs has revolutionized access to these devices. Researchers, clinicians, and the general public are keen to evaluate the clinical effectiveness of OTC HAs, as more individuals will likely use them for HL. This increased usage will provide valuable real-world data to understand the benefits and limitations of OTC HAs. Monitoring the outcomes and user feedback will provide insights into their effectiveness and impact on hearing rehabilitation.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/59894.
Small crystals are made by mixing a solution of a desired substance with an anti-solvent in a fluidic vortex mixer in which the residence time is less than 1s, for example 10 ms. The liquid within the fluidic vortex mixer ( 12 ) is subjected to high intensity ultrasound from a transducer ( 20, 22 ). The solution very rapidly becomes supersaturated, and the ultrasound can induce a very large number of nuclei for crystal growth. Small crystals, for example less than 5 μm, are formed. The resulting suspension is treated so as to add or remove ingredients, and then spray dried using an atomiser tuned to create small droplets in such a way that each droplet should contain not more than one crystal. Crystal agglomeration is hence prevented.
BACKGROUND: Obesity is characterized by abnormal accumulation of fat in adipose tissue. It is a major risk factor for metabolic syndrome caused by chronic inflammatory changes. Naturopathy and yogic intervention are a holistic approach. So, the present study aims to assess the effect of naturopathy and yogic intervention on inflammatory markers among obese individuals.
METHODS: In this randomized controlled trial, 262 subjects were recruited and randomized into either an experimental or control group with 131 subjects in each group aged 35 ± 9.6 years in experimental and 39.3 ± 9.6 years in control group. The experimental group received 10 days of naturopathy and yogic treatment. The control group didn't receive any naturopathy or yogic treatment. Complete blood count (CBC) was tested at baseline and after 10 days of intervention.
RESULTS: The study showed a significant reduction in white blood cells (WBC), Neutrophils, and Lymphocytes with mean values of 1.63 ± 0.38, 1.14 ± 0.25, 0.4 ± 0.09 and an increase in Platelet lymphocyte ratio (PLR) with mean value 19.84 ± 4.97 respectively with a P < .001 in experiment group when compared to the control group. The experimental group also showed a reduction in Platelet and Neutrophil lymphocyte ratio (NLR) with a mean value of 11.28 ± 3.5 & 0.18 ± 0.03 with a P = .01 when compared to the control group.
CONCLUSION: Obesity being a major risk factor for metabolic syndrome could be safely and effectively treated with naturopathy and yogic intervention by alleviating the inflammatory markers.
Stage 1 will identify the recommended Stage 2 dose using a dose-escalation process. Dose-escalation will continue until either a maximum tolerated dose is established, or a therapeutic dose is reached.
There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
The invention relates to cosmetic compositions containing agglomerates with particular particle sizes. The compositions are characterized in that they contain spherical non-porous SiO2 particles with a particle size of 0.05-1.5 μm, and other inorganic particle-shaped materials with spherical structure. The spherical SiO 2  and other inorganic materials form defined agglomerates with a particle size of 0.06 μm to 5 μm. The proportion of agglomerates in the cosmetic composition is between 0.1 and 30% wt. The aggregate-containing dispersions are produced by introducing the spherical SiO 2  step by step and in special conditions. Formulations produced with these aggregates are characterized by particularly stable and high sunscreen factors.
Disclosed is a system for supporting a veterinary practice. The system comprising an electronic network (100) that communicates with an animal device (101)worn by an animal, at least one veterinarian device (102), a processor, an animal owner device (102) and a display device. The animal device (101)with a biocompatible sensor is configured to collect wellness data from an animal and transmit the collected wellness data over the electronic network (100). The wellness data is related to compliance with a veterinarian-prescribed regimen of a prescribed medication for the animal. The veterinarian device (102) is configured to receive and display the wellness data received or processed over the electronic network (100). The animal owner device (102) is configured to send wellness data to the processor. The display device displays a graphical user interface that includes a plurality of acuatable icons. The actuatable icons are associated with a plurality of business-related functions for operating a veterinary practice and each icon is actuatable to access an associated portlet and display additional information associated with the respective function of a veterinary practice on the graphical user interface. An animal segmentation module is configured to filter and segment a plurality of individual animal records from an animal records database housing animal wellness data received from animal owner devices (102). A messaging module is configured to compose and send a message to the animal owner device (102) based on the segmented animal records. The processor is configured to generate and send an alert to the at least one veterinarian device (102) when the animal is not in compliance with the veterinarian-prescribed regimen of the prescribed medication for the animal.
OBJECTIVES: Back pain is a prevalent condition that affects 1 in 6 Australians at any time, with high associated health care costs. To date, there is limited information relating to symptom severity and recovery trajectory in people with back pain who present to the emergency department for care. A digital care pathway (DCP) can track patient outcomes following presentation with back pain. The primary aim of this protocol is to outline the co-development, implementation, and evaluation of a DCP for back pain patients who present to the emergency department.
METHODS: The primary aim will be addressed in 3 overlapping phases: Phase 1 (co-design) will include interviews with back pain patients and health care professionals from the Northern Hospital Emergency Department. Interview findings will inform education resources featured on the DCP and establish questionnaire content and frequency acceptability. Phase 2 (implementation) will include the rollout of the DCP and tracking of patient-reported outcome measures, which will be collected over 12 weeks. Phase 3 (evaluation) will include interviews with a subset of back pain patients who have participated in Phase 2 to evaluate the acceptability of the DCP and the barriers and facilitators of using the DCP.
ETHICS AND DISSEMINATION: This project has been approved via the National Health and Medical Research Council of Australia's National Mutual Acceptance Scheme by St Vincent's Hospital Human Ethics Committee (2022/PID06476), La Trobe University Research Governance (HEC#206/22), and Northern Health Research Governance (NH-2023-372687). We plan to publish the findings in a peer-reviewed journal and present them at conferences.
FIELD: cosmetics, dyes. SUBSTANCE: invention relates to staining composite for keratin fibers, in part, hair comprising direct cationic dye of required formula and quaternary ammonium salt in suitable medium. Invention relates also to methods of staining where this composite is used and to set for hair staining containing dyes of composite. Staining with proposed composites results to intense and low-selective staining and showing resistance to aggressive effects. EFFECT: valuable properties of composite. 21 cl, 3 ex
Patients given ondansetron 4mg by ED provider decision or by triage nurse. This is an observational cohort only.
Weight reducing surgery is the only effective therapy for morbid obese patients. Restrictive type surgery is safer than mal-absorptive type surgery. Laparoscopic sleeve gastrectomy is an effective surgery. In laparoscopic sleeve gastrectomy (LSG), about 90% of the stomach is surgically removed by vertical resection of the great curvature side, including the fundus. The simplicity of surgical procedures, the low occurrence of complications, and the efficiency of reducing excess weight have made LSG as a popular choice for bariatric surgery. After LSG, the amount of food eaten is drastically reduced, leading to nutritional deficiencies potentially. There is poor knowledge about the nutritional status inpatients after LSG. Some literatures suggest that LSG results in less nutritional deficiencies than Roux-en-Y gastric bypass. The aim of our study was to investigate the relationship between dietary intake and weight loss after LSG.
Following a single dose of two MINOCIN® 100 mg pellet-filled capsules administered to 18 normal fasting adult volunteers, maximum serum concentrations were attained in 1 to 4 hours (average 2.1 hours) and ranged from 2.1 to 5.1 μg/mL (average 3.5 μg/mL). The serum half-life in the normal volunteers ranged from 11.1 to 22.1 hours (average 15.5 hours).

When MINOCIN® Pellet-Filled Capsules were given concomitantly with a high-fat meal, which included dairy products, the extent of absorption of MINOCIN® Pellet-Filled Capsules was unchanged compared to dosing under fasting conditions. The mean Tmax was delayed by one hour when administered with food, compared to dosing under fasting conditions. MINOCIN® Pellet-Filled Capsules may be administered with or without food.

In previous studies with other minocycline dosage forms, the minocycline serum half-life ranged from 11 to 16 hours in 7 patients with hepatic dysfunction, and from 18 to 69 hours in 5 patients with renal dysfunction. The urinary and fecal recovery of minocycline when administered to 12 normal volunteers was one-half to one-third that of other tetracyclines.
BACKGROUND AND OBJECTIVE: Primary care providers (PCPs) use poorly organized patient information in electronic health records (EHR) within a limited time when treating patients with chronic pain. Clinical decision support (CDS) tools assist PCPs by synthesizing patient information and prompting guideline-concordant treatment decisions. A CDS tool- Chronic Pain OneSheet was developed through a user-centered design process to support PCP's decision-making for patients with chronic noncancer pain. OneSheet aggregates relevant patient information in one place in the EHR. OneSheet also guides PCPs in completing guideline-recommended opioid risk management tasks, tracking patient treatments, and documenting pain-related symptoms. Our objective was to identify barriers, facilitators, and recommendations to increase OneSheet use for chronic noncancer pain management in primary care.
METHODS: We conducted 19 qualitative interviews with PCPs from two academic health systems who had access to OneSheet in their EHR. Interview transcripts were coded to identify common themes using a modified thematic approach.
RESULTS: PCPs identified several barriers to using OneSheet, including limited time to address patient needs associated with multiple chronic conditions, resistance to changing established workflows, and complex OneSheet display. PCPs reported several facilitators to using OneSheet, such as OneSheet's ability to serve as a hub for chronic pain data, easy access to features that facilitate completing mandatory tasks and improved planning for certain patient visits. PCPs recommended prioritizing access to commonly used features, adding display customization capabilities, and expanding access to patients and other team members to increase OneSheet use.
CONCLUSION: Our findings highlight the importance of acknowledging the PCP workflow and task load when designing CDS tools. Future CDS tools should balance the extent of information provided with assisting PCPs to fulfill mandatory tasks. Expanding CDS tools to multiple care team members and patients can also lead to higher use by facilitating data entry, leading to more streamlined care delivery.
OBJECTIVES: Estimated fetal weight (EFW) is an important metric at delivery as neonates with abnormal birthweight and their mothers are at higher risk of birth complications. Data regarding optimal EFW assessment in gravidas with obesity is inconsistent, and with the increasing incidence of obesity, clarification of this question is crucial. We aimed to compare accuracy of ultrasound (US)-derived EFW and clinical assessments of EFW in predicting neonatal birthweight among gravidas with obesity.
METHODS: This prospective cohort study enrolled gravidas with obesity and a singleton pregnancy admitted for delivery at term. EFW was determined using either US biometry or clinical assessment (Leopold's maneuvers, Johnson's formula, and Insler's formula) at time of admission. Our primary outcome was accurate EFW, defined as EFW within 500 g of birthweight. Secondary outcomes included ability to predict small-for-gestational age (SGA) and large-for-gestational age (LGA) birthweights. These outcomes were compared between all EFW methods.
RESULTS: A total of 250 gravidas with a median body mass index of 36.4 kg/m2 were enrolled. Admission US outperformed Leopold's maneuvers in obtaining accurate EFW (81.6% versus 74.5%, P = .03). When comparing all methods, Johnson's and Insler's formulae performed the worst, accurately predicting EFW in only 27.4% and 14.3% of cases, respectively. Likewise, US-derived EFW outperformed Leopold's maneuvers and fundal height in the prediction of SGA and LGA neonates.
CONCLUSIONS: US is more accurate than clinical assessment of EFW in gravidas with obesity both for estimation of actual birthweight and prediction of abnormal birthweight. Universal late third-trimester or peripartum US for EFW should be considered in gravidas with obesity.
Perampanel will be administered orally once daily (QD) at bedtime. At the beginning of the Titration Period, oral perampanel will start at a dose of 2 milligrams (mg) QD. Doses of perampanel will then be up titrated in increments of 2 mg at no less than 2-week intervals according to the investigator's judgment. At the 4 mg dose, the investigator will confirm whether further dose escalation is needed based on participant response and tolerability. The investigator may adjust dosing further or leave the participant at 4 mg. The maximum dose is 12 mg. During the 39-week Maintenance Period, participants will continue to receive the perampanel dose level that was administered at the end of the Titration Period.
The heritability of susceptibility to tuberculosis (TB) disease has been well recognized. Over 100 genes have been studied as candidates for TB susceptibility, and several variants were identified by genome-wide association studies (GWAS), but few replicate. We established the International Tuberculosis Host Genetics Consortium to perform a multi-ancestry meta-analysis of GWAS, including 14,153 cases and 19,536 controls of African, Asian, and European ancestry. Our analyses demonstrate a substantial degree of heritability (pooled polygenic h2 = 26.3%, 95% CI 23.7-29.0%) for susceptibility to TB that is shared across ancestries, highlighting an important host genetic influence on disease. We identified one global host genetic correlate for TB at genome-wide significance (p<5 × 10-8) in the human leukocyte antigen (HLA)-II region (rs28383206, p-value=5.2 × 10-9) but failed to replicate variants previously associated with TB susceptibility. These data demonstrate the complex shared genetic architecture of susceptibility to TB and the importance of large-scale GWAS analysis across multiple ancestries experiencing different levels of infection pressure.
Traditional Chinese herbal medicine (CHM) has been extensively used in cardiovascular disease (CVD) in modern clinical practice, alone or in combination with conventional treatment. However, its efficacy has not been assessed extensively. From inception until August 2023, we systematically searched 5 public literature databases to conduct the umbrella review. The inclusion criterion is systematic reviews of randomized controlled trials investigating the effect of CHM in the contemporary management of CVDs. The quality of the included systematic reviews, the certainty of the evidence, and the potential risk of bias were assessed. Five hundred and thirty-nine systematic reviews, including 346 studies in Chinese and 193 in English, were selected before the quantitative synthesis. The methodological quality was generally moderate, with a median value of 11. The favorable efficacy of CHM was primarily presented on 5 main conditions: coronary artery disease, hypertension, heart failure, restenosis, and angina pectoris. CHM, with or without conventional treatment, showed a consistent beneficial effect in various CVDs. Nevertheless, the magnitude of the effect requires further investigation as the lack of relevant research and the complexity of the clinical practice of CHM.